53 results about "Lipid A synthesis" patented technology

The invention discloses an application of NSC348884 in preparation of an antibacterial drug, the bacteria of the NSC348884 are gram-negative bacteria or drug-resistant gram-negative bacteria, and the gram-negative bacteria are acinetobacter baumannii, escherichia coli, pseudomonas aeruginosa or klebsiella pneumoniae; based on an antibacterial drug high-throughput screening technology, it is found from 1280 small molecule compounds that the benzimidazole compound NSC348884 has direct bacteriostasis and sterilization effects on gram-negative bacteria and drug-resistant gram-negative bacteria, and no drug resistance is generated after the benzimidazole compound NSC348884 is continuously applied for 14 days. Further research shows that NSC348884 can interfere with lipid synthesis of gram-negative bacterium cell membranes, inhibit formation of biological membranes and induce lipid metabolism disorder, so that bacteriostatic and bactericidal effects are achieved. In addition, the NSC348884 can also enhance the sensitivity of the drug-resistant bacteria to the imipenem and the polymyxin B.

The invention relates to application of targeted intervention FBP2mRNA in preparation of a medicine for preventing and treating diabetic nephropathy, and belongs to the technical field of biomedicine. The invention provides an application of FBP2mRNA as a therapeutic target in preparation of a medicine for preventing and treating diabetic nephropathy. The NCBI (National Center of Biotechnology Information) login number of the FBP2mRNA is NM003837.4. The invention also provides an application of the shRNA for specifically interfering with the expression of the FBP2mRNA in the preparation of a medicine for preventing and treating diabetic nephropathy, wherein the nucleotide sequence of the shRNA is shown as SEQ ID NO. 1. It is found for the first time that targeted inhibition of the expression level of FBP2mRNA can effectively reduce the lipid level in mouse glomerular podocytes, reduce the expression level of lipid synthesis related genes and reduce the activity of lipid synthesis protein, and then the effect of treating diabetic nephropathy is achieved, so that FBP2mRNA can be used as a drug treatment target, and the treatment effect of diabetic nephropathy is improved. The application is applied to research, development and preparation of diabetic nephropathy prevention and treatment medicines.

A method of increasing lipid synthesis or accumulation in and optionally secretion from a mammary epithelial cell (MEC) culture is provided. The method contacts the MEC with an LXR agonist in the presence of a fatty acid to increase lipid synthesis or accumulation and optionally increase lipid secretion. Also provided is a method of producing synthetic fat globules, the method comprising: (a) isolating lipid droplets from cultured cells; (b) encapsulating the droplets with a lipid bilayer, thereby producing synthetic fat globules. Compositions thus produced are also provided.

The invention discloses a method for improving yield of progesterone in yarrowia lipolytica, which comprises the following steps: (1) constructing a biosensor responding to steroid hormone, and the nucleotide sequence of the sensor is as shown in SEQ ID No. 52; (2) a biosensor responding to steroid hormones is connected with a lipid synthesis key gene DGA1 in yarrowia lipolytica and spliced with a linearized pYRSB carrier, a recombinant plasmid pDTY316 is obtained, and the nucleotide sequence of the gene DGA1 is shown as SEQ ID No.57; the nucleotide sequence of the plasmid pYRSB is as shown in SEQ ID No. 54; (3) transforming the recombinant plasmid pDTY316 into a recombinant strain yDTY314 to obtain a recombinant strain yDTY316; and (4) carrying out shake flask fermentation on the recombinant strain yDTY316 to realize high yield of progesterone. Experiments prove that the yield of the progesterone obtained by the method is high.

This invention relates to a method for rapidly screening filamentous fungi that produce high levels of triglycerides and polyunsaturated fatty acids, belonging to the field of microbial technology. The method employs a two-stage screening strategy of "resistance primary screening – fluorescence secondary screening." In the primary screening stage, strains with strong lipid synthesis capabilities are initially screened by adding a combination of phytocyanin and quizalofop-p-ethyl inhibitors to the culture medium. In the secondary screening stage, cellophane culture technology and Nile red fluorescence staining are combined to quantitatively assess the triglyceride content of the colonies, achieving rapid and non-destructive screening. This method is simple to operate, highly efficient, and shows a significant positive correlation between fluorescence intensity and triglyceride content. It is suitable for mutagenesis breeding and industrial strain selection of oil-producing filamentous fungi such as *Morchella alpineensis*.

The application discloses a phytosterol and phytosterol ester complex agent and application thereof, wherein the complex agent comprises phytosterol and phytosterol ester with a mass ratio of 1:10. The application aims to improve the water solubility and bioavailability of phytosterol, realize synergistic effect by compounding phytosterol and phytosterol ester, interfere with the lipid acquisition of coccidia from multiple targets, up-regulate the expression of cecal tight junction protein to repair the intestinal barrier, inhibit the release of serum and cecal pro-inflammatory factors to relieve inflammatory reaction, regulate the expression of genes related to lipid synthesis and fatty acid oxidation to remodel lipid metabolism homeostasis, and then effectively inhibit the growth and development of coccidia, and significantly improve the growth performance of broilers infected with coccidia.

The present disclosure is directed to the treatment of diseases or conditions characterized by the buildup of fatty tissue, or hyperphagia, such as Prader-Willi syndrome, obesity, metabolic syndrome, type II diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in a reduced rate of weight gain, weight loss, and / or reduction in fatty tissue, and a marked decrease in lipid synthesis and accumulation.

The invention relates to application of DOP (dioctyl phthalate) in preparation of medicines for regulating lipid metabolism, resisting diabetes and resisting intestinal microorganisms. The DOP significantly alleviates DIO by inhibiting the expansion of lipid droplets (LD) in white adipose tissue (WAT) and down-regulating LD-related genes (including PLIN2 and PLIN3). DOP can target visceral fat, significantly improve visceral fat hypertrophy and hyperplasia (especially epididymal fat EAT is taken as aboriginal) induced by high fat diet (HFD), inhibit formation of lipid droplets, reduce expression of lipid droplet coating protein PLIN2 / 3, and block the accumulation process of lipid droplets (LD). Consistent with we have observed that DOP also inhibits the expression of genes associated with lipid synthesis and adipogenesis, including Fabp1, Fast, Ldlr, Cebpb, and Dio2. These findings show that DOP can improve diet-induced obesity by regulating lipid droplet-related pathways.

The invention provides an application of ethyl lactate in prevention and treatment of alcoholic related liver diseases. Specifically, animal experiments are carried out by establishing an alcoholic related liver disease mouse model, and in-vivo and in-vitro experiments are carried out to verify that the ethyl lactate dose-dependently improves the alcoholic related liver disease. Experiments show that ethyl lactate inhibits alcohol-induced lipid synthesis, and the liver metabolism level is regulated by up-regulating expression of SIRTI and FGF21, so that the alcoholic related liver diseases are improved. Based on the invention, the ethyl lactate or the pharmaceutically acceptable salt thereof can be used for preparing the medicine for preventing and treating the alcoholic related liver diseases.

The invention discloses application of a lipid synthesis inhibitor in treatment of breast cancer. Researches prove that F.n colonization exists in breast cancer tissues, and the F.n can regulate and control lipid deposition related gene expression and lipid metabolism change of tumor-related macrophages, so that lipid deposition of the macrophages and proliferation, invasion and migration capabilities of tumor cells are promoted; after the lipid deposition inhibitor is added, the lipid metabolism disorder of the tumor-associated macrophages can be inhibited, the tumor malignant phenotype is finally inhibited, and the treatment of the breast cancer is realized. The invention provides a new potential therapeutic target and a new therapeutic drug for effective treatment of breast cancer.

A use of uridine diphosphate glucose (UDPG) in treatment of abnormal liver glucolipid metabolism. Specifically, a use of UDPG or a pharmaceutical composition comprising same in the preparation of a drug for preventing and / or treating abnormal liver glucolipid metabolism, wherein the abnormal liver glucolipid metabolism is preferably nonalcoholic fatty liver disease, dyslipidemia and related cardiovascular diseases. Treatment using UDPG can reduce lipid synthesis and lipid synthesis related gene expression in the liver.

The invention discloses recombinant escherichia coli for producing monophosphoryl lipoid A. The recombinant escherichia coli is used for producing monophosphoryl lipoid A. The gene of the chassis bacterium of the recombinant Escherichia coli for coding the enzyme of the lipid A synthetic pathway is replaced by an exogenous gene for coding the enzyme of the lipid A synthetic pathway, and contains an exogenous gene for coding pagL and an exogenous gene for coding lpxE. The invention also discloses a method for preparing the recombinant Escherichia coli, a method for preparing the monophosphoryl lipid A and application of the Escherichia coli in preparation of vaccine adjuvants. When the recombinant Escherichia coli provided by the invention is used for preparing the monophosphoryl lipid A, the pathogenic risk is avoided, and the strain has no antibiotic selection marker, so that safe, green and large-scale industrial production is facilitated. The strain can also be used as a chassis strain for further modification of the lipoid A structure.

The present application belongs to the field of microalgae biotechnology, microalgae culture regulation and high-value lipid bio-manufacturing, and specifically relates to a method for improving microalgae biomass and eicosapentaenoic acid (EPA) yield by regulating amino acids, which takes microalgae capable of synthesizing EPA as a culture object, adds exogenous amino acids or amino acid combinations to the culture system under non-stress culture conditions containing sufficient inorganic nitrogen source, regulates photosynthesis, growth metabolism and lipid synthesis process of the microalgae, and simultaneously improves microalgae biomass and EPA volumetric yield; by adding specific exogenous amino acids or amino acid combinations under the condition of sufficient nutrition culture, the present application realizes synchronous promotion of microalgae growth and EPA accumulation. Different from traditional methods of relying on stress such as nitrogen deficiency to induce lipid accumulation, the present application can improve microalgae biomass, photosynthetic performance, pigment yield and EPA volumetric yield without significantly inhibiting cell growth and photosynthetic activity.

The invention relates to a quaternary lipid barrier repairing composition which is prepared from the following raw materials: tea-seed oil, camellia-seed oil, a phytosterol derivative and meadowfoam seed oil. Through compounding of the tea-seed oil, the camellia-seed oil, the phytosterol derivative and the meadowfoam seed oil, multi-dimensional barrier repair synergy of passive supplement, active repair and antioxidant protection is realized. The quaternary lipid system is highly similar to a human body sebum membrane structure, and can rapidly fill up cuticle lipid gaps, significantly reduce transdermal moisture loss and efficiently repair a skin physical barrier; the phytosterol derivative can be cooperated with the tea-seed oil and the camellia-seed oil, lipid components can be directly supplemented, a skin lipid synthesis mechanism can be activated, skin endogenous generation proportion-coordinated cholesterol-ceramide-free fatty acid is guided, and self-reconstruction of a barrier is achieved; the meadowfoam seed oil has excellent oxidation resistance, so that secondary damage of oxidative stress to lipid can be effectively resisted, and the stability and durability of repair are ensured.

The present invention belongs to the field of biotechnology, and in particular, relates to a method for oversupplying cytoplasmic acetyl-CoA and a related strain construction method. The present invention first analyzes the various destinations of intracellular acetyl-CoA, and reduces the flux of acetyl-CoA to lipid synthesis by enzyme engineering means, which effectively increases the level of cytoplasmic acetyl-CoA without affecting strain growth; further, the present invention also characterizes the endogenous peroxidase / mitochondrial carnitine acyl transfer pathway of Yarrowia lipolytica, which effectively increases cytoplasmic acetyl-CoA while clarifying the transport mode of the yeast; finally, the present invention further increases the cytoplasmic acetyl-CoA content by accelerating lipid recycling. These diverse and multi-angle metabolic engineering strategies broaden the cytoplasmic acetyl-CoA capacity, perform well in constructing cell factories for producing compounds with acetyl-CoA as precursors, and have wide application value.

The invention provides application of polypeptide for blocking lipid synthesis in treatment of tumor and lipid metabolism abnormality diseases. Specifically, the invention discloses a polypeptide, and the polypeptide has the effects of inhibiting phosphorylation of Insig1 / 2 and inhibiting lipid synthesis. Nucleic acid molecules encoding the polypeptides, corresponding expression vectors and host cells, and methods of producing the polypeptides of the invention are also disclosed. The polypeptide provided by the invention can be combined with PCK1pS90 with high affinity, and can be used for detection of PCK1pS90 and targeted therapy of tumor or lipid metabolism diseases.

The present invention relates to the synthesis of a peptide-based ionizable lipid and the use thereof, and specifically relates to an amino acid molecular building block with an alkylated side-chain primary amino group, a peptide-based ionizable lipid (PIL) formed therefrom, a method for synthesizing PIL, and a PIL library containing a plurality of PILs. The present invention further relates to a lipid nanoparticle (LNP) containing PIL, in particular a PIL-mediated organ-targeted LNP (PILOT LNP), a pharmaceutical composition containing same, and a targeted delivery method for administering the LNP or the pharmaceutical composition, or a method for preventing or treating a disease.

The present invention relates to a composition for regulating hepatic lipid metabolism, comprising Lactiplantibacillus plantarum OPT-A1 strain deposited under accession number KCTC 15555BP, a culture liquid thereof, a cultured product thereof, or a culture lysate thereof. The composition suppresses lipid accumulation and expression of genes related to lipogenesis in hepatocytes, and enhances expression of genes related to lipid oxidation. In addition, the composition inhibits accumulation of triglycerides in hepatocytes and reduces blood triglyceride levels, total cholesterol levels, and liver injury indices. Furthermore, the composition promotes rapid consumption of lipids in hepatocytes and somatic cells through enhancement of muscle mass, and thus can be advantageously used as a raw material for foods, pharmaceuticals, and the like related to alleviation and treatment of various metabolic diseases.

Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and / or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders, such as non-alcoholic steatopepatitis (NASH).

The invention provides application of a TNFRSF13B gene in regulating and controlling the adaptive capacity of Hu sheep to a drought environment, and belongs to the technical field of molecular breeding. The invention provides an application of a TNFRSF13B gene in regulating and controlling the adaptive capacity of Hu sheep to a drought environment. Reduction of TNFRSF13B gene expression leads to enhancement of lipid synthesis capability and glucose uptake capability of Hu sheep liver cells and reduction of lipid decomposition capability, and after Hu sheep is introduced into the Hetian region in the arid region and the Taihu Lake region, in order to well adapt to local climatic environment, the Hu sheep becomes smaller in body form and is also improved in lipid synthesis capability, the Hu sheep is reduced in lipid decomposition capability. Therefore, in order to adapt to the drought environment, the TNFRSF13B gene has high methylation and low expression and participates in a signal channel of energy metabolism, and reference is provided for improving the ability of sheep to adapt to the drought environment.

The application discloses application of an SMOC1 gene in regulating FAPs adipogenic differentiation and intramuscular fat deposition, and belongs to the technical field of genetic engineering and animal genetic breeding. The application research finds that the SMOC1 gene has important positive regulation on FAPs adipogenic differentiation and IMF deposition, overexpression of the SMOC1 can promote expression of PPARgamma and downstream fat generation genes and lipid synthesis related genes, positively regulate lipid synthesis and lipid droplet accumulation, promote intramuscular fat deposition, and improve meat quality. The application provides a new molecular marker and gene operation target for livestock and poultry variety selection, intramuscular fat precise regulation, and has important industrial application value.

The present application relates to furan ring compounds, and to related salts, solvates, prodrugs, and compositions. The compound can improve liver injury induced by APAP and / or OA / PA, can improve up-regulation of inflammatory factors IL-6 and TNF-alpha and lipid synthesis genes PPAR gamma and FABP1 in the liver injury, can promote expression of a cell proliferation gene Ki67, and can be used as a medicine and a lead compound for treating liver diseases.

The invention belongs to the field of biotechnology and medical technology, and particularly relates to application of a PPAR gamma agonist in preparation of a medicine for preventing, relieving or treating preeclampsia. Experiments find that placenta lipid metabolism abnormality of preeclampsia patients is closely related to PPAR gamma-mediated lipid synthesis increase and metabolic regulation imbalance in an anoxic environment, which shows as trophoblast invasion and migration dysfunction, while the PPAR gamma agonist rosiglitazone can relieve trophoblast dysfunction caused by hypoxia. The PPARgamma antagonist T0070907 can aggravate trophoblast dysfunction caused by hypoxia, and the PPARgamma agonist can be used for preparing the medicine for preventing, relieving or treating preeclampsia, so that preeclampsia treatment is realized, and the life quality and the survival rate of patients are further improved.

The invention provides application of charred rehmannia phenylethanoid glycoside B1 in preparation of a product for treating and / or preventing glioblastoma, and belongs to the technical field of biological medicine. The research finds that the charred rehmannia phenethyl alcohol glycoside B1 is specifically combined with TRAF2, so that the TRAF2 is blocked from performing polyubiquitination modification on K63 of FASN, degradation is promoted, and lipid synthesis in glioblastoma cells is inhibited, thereby promoting tumor cell apoptosis, inhibiting proliferation and migration and finally inhibiting tumor growth. The charred rehmannia phenylethanoid glycoside B1 has good anti-glioblastoma activity, has low toxicity to normal cells, and provides more choices and possibilities for treatment of glioblastoma.

The present invention belongs to the technical field of cosmetics, and discloses a composition for inhibiting sebum secretion and shrinking pores, as well as a preparation method and application. The composition of the present invention comprises the following components: angustifolia extract, kudzu root extract, plankton extract, olive leaf extract and medicinal pore fungus extract. The composition of the present invention is obtained by compounding angustifolia extract, kudzu root extract, plankton extract, olive leaf extract and medicinal pore fungus extract. On the basis of astringing pores, it innovatively combines the following pathways: reducing IGF-1-induced lipid synthesis, inhibiting acetyl-CoA carboxylase for de novo fatty acid synthesis, and down-regulating COX-2 gene expression. These multiple pathways work together to achieve the purpose of long-term inhibition of sebum secretion and shrinking pores.

The invention discloses a phytosterol and phytosterol ester complexing agent and application thereof, and the complexing agent comprises phytosterol and phytosterol ester in a mass ratio of 1: 10. By compounding the phytosterol and the phytosterol ester, the water solubility and bioavailability of the phytosterol are improved, and the synergistic interaction is realized; starting from multiple targets, cecum tight junction protein expression is up-regulated to repair intestinal barriers, release of serum and cecum proinflammatory factors is inhibited to relieve inflammatory response and lipid synthesis and fatty acid oxidation related gene expression are regulated and controlled to remodel lipid metabolism homeostasis while obtaining of coccidium lipid is interfered; further, the growth and development of coccidiosis are effectively inhibited, and the growth performance of coccidiosis infected broiler chickens is remarkably improved.

Disclosed in the present invention are a class of dienyl long-chain compounds, and a preparation method therefor and the use thereof. The structure is as shown in formula I, and the definition of each substituent in the formula is as described in the description and the claims. The compound of the present invention has an ACLY inhibitory activity and a lipid synthesis inhibitory activity, and can be used in the preparation of a drug for treating metabolic diseases such as hyperlipidemia and atherosclerosis, or a variety of cancers such as lung cancer, pancreatic cancer, breast cancer, ovarian cancer, liver cancer, intestinal cancer, brain cancer and acute myeloid leukemia.

The invention relates to the technical field of poultry breeding, and particularly provides a novel application of miR-363-5p. A hepatocyte model is established through overexpression and knock-down of the miR-363-5p so as to detect key indexes related to lipid synthesis, oxidative stress and inflammatory factors, and research results show that inflammatory response in chicken hepatocytes can be inhibited, oxidative stress can be reduced and lipid degradation can be prevented by reducing expression of the miR-363-5p. In addition, the invention also finds that the development of chicken liver cells is controlled by targeting the miR-363-5p to the CPEB2, ERK signal transduction can be activated by knocking down the miR-363-5p or overexpressing the CPEB2, so that the miR-363-5p-CPEB2-MAPK / ERK axis is determined to be a key regulatory factor in the pathogenesis of the chicken fatty liver. Therefore, the miR-363-5p and / or CPEB2 gene can be used as a detection target to develop a reagent or a kit for diagnosing the chicken fatty liver syndrome.

The invention provides an efficient cultivation method for Hilasiosira wiskei rich in EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid). The efficient cultivation method comprises the following steps of S1, seawater pretreatment, S2, basic culture medium preparation and nutritive salt optimization, S3, algae seed inoculation, S4, illumination management, S5, temperature management, S6, plant extract addition and S7, targeted liposome-precursor compound addition. By adding the willow bark extract, the rape pollen extract and the pine bark extract, and by activating a lipid synthesis pathway, enhancing the oxidation resistance, regulating cell metabolism, coordinating signal amplification and other mechanisms, the EPA content and the DHA content of the Halasiosira wiskei are remarkably increased. By adding the targeted liposome-precursor compound, the targeted liposome-precursor compound is specifically combined with the surface of an algae cell, and enters the cell through membrane fusion or endocytosis to realize targeted delivery, so that the utilization rate of alpha-linolenic acid is increased, and the EPA and DHA contents of the halasiosira wiskei are increased.